Showing results (61-70 of 776) with videos related to
Sort By:
Pageof 78
Cancer Research|July 5, 2002
Cytokines modulate telomerase activity in a human multiple myeloma cell lineMasaharu Akiyama, Teru Hideshima, Toshiaki Hayashi, et al.The Journal of Biological Chemistry|March 11, 2004
Critical role for hematopoietic cell kinase (Hck)-mediated phosphorylation of Gab1 and Gab2 docking proteins in interleukin 6-induced proliferation and survival of multiple myeloma cellsKlaus Podar, Gustavo Mostoslavsky, Martin Sattler, et al.Cell Cycle (Georgetown, Tex.)|January 19, 2005
Proteasome inhibition in the treatment of cancerPaul G Richardson, Constantine Mitsiades, Teru Hideshima, et al.British Journal of Haematology|January 18, 2006
Novel therapeutic strategies targeting growth factor signalling cascades in multiple myelomaHiroshi Yasui, Teru Hideshima, Paul G Richardson, et al.Blood|January 19, 2006
Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cellsTeru Hideshima, Laurence Catley, Hiroshi Yasui, et al.Cancer Research|September 17, 2005
A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cellsDharminder Chauhan, Guilan Li, Klaus Podar, et al.Blood|April 14, 2005
Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myelomaNoopur Raje, Shaji Kumar, Teru Hideshima, et al.Annual Review of Medicine|January 18, 2006
Bortezomib: proteasome inhibition as an effective anticancer therapyPaul G Richardson, Constantine Mitsiades, Teru Hideshima, et al.Current Pharmaceutical Biotechnology|November 2, 2006
Recent advances in the treatment of Multiple MyelomaHiroshi Yasui, Teru Hideshima, Paul G Richardson, et al.Blood|May 27, 2006
Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cellsLaurence Catley, Ellen Weisberg, Tanyel Kiziltepe, et al.Pageof 78